Oncotarget

Research Papers: Pathology:

Molecular–genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort

Saeko Hayashi, Hikaru Sasaki _, Tokuhiro Kimura, Takayuki Abe, Takumi Nakamura, Yohei Kitamura, Tomoru Miwa, Kaori Kameyama, Yuichi Hirose and Kazunari Yoshida

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:15871-15881. https://doi.org/10.18632/oncotarget.3869

Metrics: PDF 1203 views  |   HTML 2173 views  |   ?  


Abstract

Saeko Hayashi1, Hikaru Sasaki1, Tokuhiro Kimura2,7, Takayuki Abe3, Takumi Nakamura1, Yohei Kitamura4, Tomoru Miwa1, Kaori Kameyama5, Yuichi Hirose6 and Kazunari Yoshida1

1 Department of Neurosurgery, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan

2 Department of Pathology, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan

3 Center for Clinical Research, Department of Preventive Medicine and Public Health, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan

4 Department of Neurosurgery, Saiseikai Utsunomiya Hospital, Takebayashi, Utsunomiya, Tochigi, Japan

5 Division of Diagnostic Pathology, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan

6 Department of Neurosurgery, Fujita Health University School of Medicine, Kutsukake-cho, Toyoake, Aichi, Japan

7 Present address: Department of Pathology, Yamaguchi University Graduate, School of Medicine, Minami-kogushi, Ube, Yamaguchi, Japan

Correspondence to:

Hikaru Sasaki, email:

Keywords: total 1p19q loss; 1p19q codeletion; astrocytic; ATRX; p53

Received: March 08, 2015 Accepted: April 02, 2015 Published: May 11, 2015

Abstract

The prognostic significance of 1p19q loss in astrocytic gliomas has been inconclusive.

We collected 57 gliomas with total 1p19q loss from among 218 cases of WHO grade-II/III gliomas operated at Keio University Hospital between 1990 and 2010. These tumors were classified as oligodendroglial or “astrocytic” by a WHO-criteria-based institutional diagnosis. Chromosomal copy number aberrations (CNAs), IDH 1/2 mutations, MGMT promoter methylation, and expression of p53 and ATRX were assessed. Survival outcome was compared between the two histological groups.

Of the 57 codeleted gliomas, 37, 16, and four were classified as oligodendroglial, “astrocytic”, and unclassified, respectively. Comparative genomic hybridization revealed that although chromosome 7q/7 gain was more frequent in “astrocytic” gliomas, other CNAs occurred at a similar frequency in both groups. None of the “astrocytic” gliomas showed p53 accumulation, and ATRX loss was found in three of the 15 “astrocytic” gliomas. The estimated overall survival (OS) curves in the patients with codeleted oligodendroglial and “astrocytic” gliomas overlapped, and the median OS was 187 and 184 months, respectively. Histopathological re-assessment by a single pathologist showed consistent results.

Gliomas with total 1p19q loss with “astrocytic” features have molecular and biological characteristics comparable to those of oligodendroglial tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3869